RBC Capital lowers Biogen (NASDAQ:BIIB) price target from $379 to $374

By / / Biogen, Royal Bank of Canada

RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $379 to $374.

Scroll to Top